703. Cellular Immunotherapies other than CAR-T Cells: Basic and Translational: Poster I

TCR T cells targeting a public neoantigen produced by the SF3B1 K700E mutation kill SF3B1 mutant AML MDS

TCR T cells expressing a TCR recognizing the MPO propeptide derived MPO132 140 HLA a 02 01 specifically kill AML and spare healthy myeloid cells

Acute Myeloid Leukemia eradication targeting cathepsin g with a dual HLA restricted TCR

Pretargeted glycoengineered NK cell PG NK therapy A universal off the shelf platform redefining targeted cell therapy strategies in lymphoma

PARP1 inhibition sensitizes AML to CD123 CAR NK cells via immunophenotypic remodeling

Overcoming maturation deficits in iPSC NK cells through programmable T bet induction

CD84 CD3 bispecific antibody achieves potent anti leukemic activity with favorable safety profile in Acute Myeloid Leukemia

Ex vivo expanded adaptive NK cells in combination with a bispecific NK cell engager targeting BCMA for synergistic control of multiple myeloma

Development of a novel multiomic sequencing approach to characterize infused donor memory like NK cells in an immune compatible environment